nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations
|
Boeve, Bradley F |
|
|
21 |
3 |
p. 258-272 |
artikel |
2 |
Advancing the diagnosis of repeat expansion disorders
|
Lockhart, Paul J |
|
|
21 |
3 |
p. 205-207 |
artikel |
3 |
Arianna Tucci
|
|
|
|
21 |
3 |
p. 222 |
artikel |
4 |
Brain health in the Philippines
|
Osorio, Lorena Margarita B |
|
|
21 |
3 |
p. 216-217 |
artikel |
5 |
Brains are neither pink nor blue but fifty shades of grey matter
|
Ranscombe, Peter |
|
|
21 |
3 |
p. 223 |
artikel |
6 |
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
|
Al-Hassany, Linda |
|
|
21 |
3 |
p. 284-294 |
artikel |
7 |
CGRP-targeted drugs for migraine: still many uncertainties
|
Diener, Hans Christoph |
|
|
21 |
3 |
p. 209-210 |
artikel |
8 |
Correction to Lancet Neurol 2022; 21: 125–39
|
|
|
|
21 |
3 |
p. e3 |
artikel |
9 |
Correction to Lancet Neurol 2022; 21: 42–52
|
|
|
|
21 |
3 |
p. e3 |
artikel |
10 |
Correction to Lancet Neurol 2022; 21: 189–202
|
|
|
|
21 |
3 |
p. e3 |
artikel |
11 |
Correction to Lancet Neurol 2019; 18: 329–31
|
|
|
|
21 |
3 |
p. e3 |
artikel |
12 |
Expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study
|
The Lancet Neurology Editors, |
|
|
21 |
3 |
p. 210 |
artikel |
13 |
Karin Klijn: driven by a love of neurology and equality
|
Venkatesan, Priya |
|
|
21 |
3 |
p. 221 |
artikel |
14 |
Making a difference for motor neuron diseases
|
Samarasekera, Udani |
|
|
21 |
3 |
p. 219-220 |
artikel |
15 |
Management of atherosclerotic extracranial carotid artery stenosis
|
Bonati, Leo H |
|
|
21 |
3 |
p. 273-283 |
artikel |
16 |
MOG antibody-associated disease after vaccination with ChAdOx1 nCoV-19
|
Francis, Anna |
|
|
21 |
3 |
p. 217-218 |
artikel |
17 |
Multiple sclerosis: two decades of progress
|
Cree, Bruce A C |
|
|
21 |
3 |
p. 211-214 |
artikel |
18 |
Rare diseases: maintaining momentum
|
The Lancet Neurology, |
|
|
21 |
3 |
p. 203 |
artikel |
19 |
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial
|
Velázquez-Pérez, Luis |
|
|
21 |
3 |
p. 204-205 |
artikel |
20 |
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial
|
Coarelli, Giulia |
|
|
21 |
3 |
p. 225-233 |
artikel |
21 |
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
|
Benkert, Pascal |
|
|
21 |
3 |
p. 246-257 |
artikel |
22 |
The crucial history of Down syndrome
|
Zaman, Shahid |
|
|
21 |
3 |
p. 222 |
artikel |
23 |
The pain of a migraine
|
Morgan, Jules |
|
|
21 |
3 |
p. 224 |
artikel |
24 |
The prognostic value of neurofilament light chain in serum
|
Sellebjerg, Finn |
|
|
21 |
3 |
p. 207-208 |
artikel |
25 |
The reality of multiple sclerosis assessment in middle-income countries
|
Abramov, Dimitri Marques |
|
|
21 |
3 |
p. 215 |
artikel |
26 |
The reality of multiple sclerosis assessment in middle-income countries – Authors' reply
|
Rovira, Àlex |
|
|
21 |
3 |
p. 215-216 |
artikel |
27 |
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study
|
Ibañez, Kristina |
|
|
21 |
3 |
p. 234-245 |
artikel |